Oraya Therapeutics, Inc. Report issue

For profit
Founded: Newark CA United States (2007)
Status: Acquired by Carl Zeiss Meditec, Inc. (2016)

Organization Overview

First Clinical Trial
2012
NCT01521819
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Other Trials (1)

ranibizumab (lucentis) (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1